reference/10675399

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/10675399

Outgoing Links

Predicate	Object
contentType	Journal Article\|Research Support, Non-U.S. Gov't
endingPage	1340
issn	1097-0215 0020-7136
issueIdentifier	6
pageRange	1333-1340
publicationName	International Journal of Cancer
startingPage	1333
bibliographicCitation	Müller J, Ehlers A, Burkhardt L, Sirma H, Steuber T, Graefen M, Sauter G, Minner S, Simon R, Schlomm T, Michl U. Loss of p^Ser2448‐mTOR expression is linked to adverse prognosis and tumor progression in ERG‐fusion‐positive cancers. Intl Journal of Cancer. 2012 Aug 30;132(6):1333–40. doi: 10.1002/ijc.27768.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-0158-4258 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d1d26a878669cdeb905644c18540c6aa http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9e495a54d5d2efd66d5bf4c5567be33c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bbabb7fb387c9dd0ffd22d15ba1d3adc http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cfa890515f4247406c25f6ecb6e94d8a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c573803e3a46d13c840101c888caea5f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_beb2593497231dc040ef0d3ff71cd038 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_749ecc31e9d1c2b5948c150d72a59a60 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0ed62564289589db4cbcfaa5ae38d4ca http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7bf658f5336c02fdb2c07ad805b0191c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d2b8b1a86742c0bca9c44d5a42f888cb http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cf98b4df7958b12e9fe72253b8f2b95c
date	2012-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1002/ijc.27768 https://pubmed.ncbi.nlm.nih.gov/22886792
isPartOf	https://portal.issn.org/resource/ISSN/1097-0215 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/4284 https://portal.issn.org/resource/ISSN/0020-7136
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Loss of pSer2448‐mTOR expression is linked to adverse prognosis and tumor progression in ERG‐fusion‐positive cancers
discusses	http://id.nlm.nih.gov/mesh/M0479128 http://id.nlm.nih.gov/mesh/M0195964 http://id.nlm.nih.gov/mesh/M0282104 http://id.nlm.nih.gov/mesh/M000613727 http://id.nlm.nih.gov/mesh/M0543256 http://id.nlm.nih.gov/mesh/M0469193 http://id.nlm.nih.gov/mesh/M0023900
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D050939 http://id.nlm.nih.gov/mesh/D015534Q000235 http://id.nlm.nih.gov/mesh/D058570Q000502 http://id.nlm.nih.gov/mesh/D011471Q000209
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D058570Q000032 http://id.nlm.nih.gov/mesh/D051059Q000235 http://id.nlm.nih.gov/mesh/D011471Q000235 http://id.nlm.nih.gov/mesh/D016016 http://id.nlm.nih.gov/mesh/D017353 http://id.nlm.nih.gov/mesh/D018450 http://id.nlm.nih.gov/mesh/D000071230 http://id.nlm.nih.gov/mesh/D011471Q000473 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D011471Q000737 http://id.nlm.nih.gov/mesh/D011379 http://id.nlm.nih.gov/mesh/D010766
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_fe0d872c4ea3e7d9f07488fc82841cc8 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_bcd6f21312d21a5cf3f0a82f59d9ac97 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_c582dec943ff7b743aa0691df291cea6 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5284616 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_472b28cee6c37ce9d58de4aa1dc6d7ef http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8983 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_d0bb789479d34dbc0811f92fc2bc5049 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5951

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID2078 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID2475

Total number of triples: 67.